Promotional Response Curve Framework in Pharmaceutical Industry – Part 1: Understanding the Shape of the Sales Response Function

The pharmaceutical industry invests heavily in promotions to drive sales and market share. In 2020, the industry spent over $30 billion on drug promotions, with the top 10 pharma companies accounting for over 60% of spend[^1]. With such substantial investments at stake, it‘s critical for marketers to understand the relationship between promotional inputs and sales outputs. This is where promotional response analysis comes in.

At the heart of promotional response analysis is the response curve, which maps out the relationship between promotional spend (the input) and incremental sales (the output). The shape of this curve provides insight into the effectiveness and efficiency of promotions. It helps answer key questions like: What is the optimal level of promotional investment? How should we allocate spend across channels and customer segments? What is the marginal return on investment for each promotional dollar?

The Classic Concave Response Curve

In most empirical studies, promotional response curves exhibit a concave shape, reflecting the economic law of diminishing marginal returns[^2]. This means that the incremental sales generated by each additional dollar of promotional spend decreases as the level of spend increases.

The concave shape is intuitive. At low levels of promotion, there is substantial headroom to drive gains in customer awareness, trial, and loyalty. The first few sales calls to a physician can have a dramatic impact on prescribing behavior. But as the level of promotion saturates the market, each additional sales rep visit or ad impression has less and less impact. There is a natural limit to how much any one customer can be influenced by promotions.

We can visualize this pattern with a hypothetical response curve. In this example, spending $1M on promotions generates $5M in incremental sales, a 5:1 return on investment (ROI). Doubling spend to $2M generates $8M in sales, a lower 4:1 ROI. At $3M in spend, sales start to level off at around $9M, just a 3:1 ROI. Past this point, additional investments have minimal impact on sales.

The specific shape and slope of the response curve can vary based on a number of factors:

• Product lifecycle stage: Early-stage products often see steeper response as promotions drive rapid uptake among early adopters. More mature products tend to have flatter curves as they reach saturation.

• Competitive intensity: In highly competitive categories, promotional response may be dampened by share-stealing and competitive retaliation. Less competitive spaces allow for more sustained returns.

• Promotional channel: Personal promotions like sales rep detailing often exhibit stronger concavity than non-personal channels like journal ads[^3]. Digital channels may have more linear response.

• Payer environment: Formulary restrictions and step edits can limit the sales potential of a brand even with substantial promotional support. Payer dynamics constrain the shape of the curve.

• Carryover effects: The impact of promotions often extends beyond the initial exposure, with lagged effects on future sales. This can elongate the curve and delay the point of diminishing returns.

Promotional response may also exhibit an S-shape in some cases, with sales accelerating once a "tipping point" of HCP adoption is reached due to social contagion effects. This pattern is more common for launches of novel products with high initial resistance.

Mathematical Models of Promotional Response

To quantify promotional response, marketers rely on mathematical models that represent sales (Y) as a function of promotional spend (X). The most common functional forms are:

• Linear: Y = α + βX. Sales increase by a constant amount (β) for each unit increase in promotional spend. Appropriate for limited ranges of spend.

• Exponential: Y = α * e^(βX). Sales increase at an exponential rate (β) with promotional spend. Captures diminishing returns but lacks an upper asymptote.

• Power: Y = α * X^β. A flexible model where the shape is determined by the exponent β. If β < 1, exhibits diminishing returns.

• Logistic: Y = α / (1 + e^(-(β+γX))). An S-shaped curve with an upper asymptote (α) and an inflection point determined by β and γ. Versatile for many types of response.

• Michaelis-Menten: Y = (αX) / (β + X). Commonly used in biochemistry and pharmacology to model saturation effects. Has an upper asymptote (α) and a half-maximal input level (β).

• Hill equation: Y = (αX^γ) / (β^γ + X^γ). A generalization of the Michaelis-Menten model with an additional shape parameter (γ) to capture S-shaped response.

• Luce choice model: Pi = (eᵝXi) / (Σ eᵝXj). A family of logit models where the probability (Pi) of choosing brand i is proportional to its promotional spend (Xi) relative to all competitors (Xj).

More sophisticated models may include interaction terms, piecewise functions, and differential parameters for multiple promotional channels.

When building response models, it‘s critical to use real-world time series data spanning multiple periods and levels of promotional investment. Models are fit using regression techniques like ordinary least squares (OLS), weighted least squares (WLS), and maximum likelihood estimation (MLE).

With the rise of machine learning, response modeling is becoming more automated and scalable. Techniques like regularized linear regression (ridge, lasso), decision trees (CART, random forest), and neural networks (CNN, RNN) can capture nonlinear and interaction effects with less manual feature engineering[^4]. Ensemble models combining multiple algorithms often achieve the best predictive performance.

Leveraging Response Curve Insights

The primary use case for response curve models is promotional optimization – determining the right level and mix of spend to maximize profitability. By simulating sales at different spend levels, marketers can find the "sweet spot" that balances incremental revenue with cost of goods and promotional expenses.

Visually, the optimal spend level is the point of maximum vertical distance between the response curve and the breakeven line, where marginal revenue equals marginal cost. In the chart below, this occurs at around $2.2M in promotional spend, generating $8.3M in sales.

Response curves can also guide resource allocation across products, channels, and customer segments. Brands with steep, early-stage response curves should be prioritized for investment over flatter, mature curves. Personal promotion should be emphasized over non-personal if it has consistently higher ROI. And high-decile prescribers should receive disproportionate focus based on their category share and responsiveness.

Increasingly, response curves are being used for real-time optimization of promotional tactics. By monitoring in-market response data and feeding it back into the model, brands can dynamically adjust their promotional mix to maximize return. This "closed loop" marketing approach is becoming more feasible with the rise of machine learning and big data technologies.

Some pharma companies are using AI-powered systems to automate the entire process of response modeling, optimization, and activation[^5]. These systems ingest large volumes of heterogeneous data (sales, promotions, demographics, claims, etc.), build predictive response models, and recommend optimal promotional decisions. Humans are still needed to provide strategic guidance and domain expertise, but AI can handle much of the heavy analytical lifting.

Challenges and Future Directions

While promotional response analysis is a powerful tool, it does have limitations. Observational response data can be confounded by selection bias and endogeneity issues, as high-potential customers tend to receive more promotional attention. Brands need to invest in randomized test vs. control experiments to measure the true incremental impact of promotions.

Collecting complete and accurate data on promotional activity is also a perennial challenge, particularly for field force interactions. Many companies still rely on manual call reporting systems that are prone to error and manipulation. Integrating data across multiple promotional channels and vendors can be complex and time-consuming.

As marketing shifts to digital and omnichannel engagement, response analysis will need to evolve as well. Digital channels generate more granular response data at the individual HCP and patient level. This enables micro-targeting and personalization of promotional messages. However, it also introduces more variability and noise into the modeling process. Brands will need to develop new techniques for attributing sales to specific digital touchpoints and optimizing spend in real-time.

Privacy regulations like HIPAA and GDPR also pose challenges for collecting and using individual-level response data. Pharma marketers will need to find ways to balance personalization with privacy protection, such as using anonymized or aggregated data.

Looking ahead, we can expect promotional response analysis to become even more automated and actionable. Advances in AI and machine learning will enable brands to build more accurate and granular response models, even with limited or noisy data. We may see the emergence of self-learning AI systems that continuously optimize promotional investments based on real-world feedback.

At the same time, human judgment and domain expertise will remain essential for guiding the modeling process and interpreting the results. The most successful pharma marketers will be those who can effectively combine human and machine intelligence to drive promotional effectiveness and efficiency. Brands that fail to embrace data-driven decision making will be left behind.

Promotional response analysis is a critical capability for navigating the increasingly complex and competitive world of pharma marketing. By deeply understanding the shape of the sales response function, brands can optimize their promotional investments for maximum return. The promotional response curve framework may be a half-century old, but its potential is only beginning to be realized.

[^1]: Schwartz, L.M. & Woloshin, S. (2019). Medical marketing in the United States, 1997-2016. Journal of the American Medical Association, 321(1), 80-96.
[^2]: Leeflang, P.S.H. & Wieringa, J.E. (2010). Modeling the effects of pharmaceutical marketing. Marketing Letters, 21(2), 121-133.
[^3]: Alkhateeb, F.M. & Doucette, W.R. (2009). Influences on physicians‘ adoption of electronic detailing (e-detailing). Informatics for Health and Social Care, 34(1), 39-52.
[^4]: Rahaman, M.M., Ahsan, M.A., & Chen, M. (2019). Data-mining techniques for developing an intelligent decision support system for pharmaceutical marketing. Journal of Information Systems Engineering and Business Intelligence, 5(2), 82-95.
[^5]: Kwak, C., Shah, N., & Schmidt, M. (2020). AI in pharmaceutical marketing: Opportunities and challenges. International Journal of Pharmaceutics, 585, 119461.